The Mechanisms of lncRNA-Mediated Multidrug Resistance and the Clinical Application Prospects of lncRNAs in Breast Cancer
Abstract
:Simple Summary
Abstract
1. Introduction
2. MDR
3. LncRNAs
3.1. The Advantages of lncRNAs
3.2. The Drawbacks of lncRNAs
4. Transcription Factors Involving in lncRNA Regulation
5. The Relationship between MDR and lncRNAs
5.1. Regulation of Cell Survival and Death
5.1.1. Suppressing Apoptosis
5.1.2. Autophagy
5.1.3. Activating DNA Repair
5.2. Regulating the Cell Cycle
5.3. Drug Efflux
5.4. Modulating the EMT Process
5.5. Epigenetic Modification
5.6. Modifying the TME via Exosomal lncRNAs
LncRNA | Type | Genomic Location | Expression Level * | Resistant Drugs | Cell Lines | Possible Mechanism § | Reference |
---|---|---|---|---|---|---|---|
AFAP1-AS1 | Oncogene | chr4p16.1 | ↑ | trastuzumab | SKBR-3; BT474 | ↑ translation of ERBB2 mRNA | [143] |
H19 | Oncogene | chr11p15.5 | ↑ | doxorubicin | MCF-7; MDA-MB-231 | N/A° | [200] |
HISLA | Oncogene | chr14q31.3 | ↑ | docetaxel | MDA-MB-231; BT-474; MDA-MB-468; MCF-7 | inhibit the hydroxylation and degradation of HIF-1α | [201] |
AGAP2-AS1 | Oncogene | chr12q14.1 | ↑ | trastuzumab | SKBR-3; BT474 | N/A | [202] |
SNHG14 | Oncogene | chr15q11.3 | ↑ | trastuzumab | SKBR-3; BT474 | ↑ Bcl-2/↓ BAX signaling pathway | [57] |
UCA1 | Oncogene | chr19q13.12 | ↑ | tamoxifen | MCF-7; LCC2 | ↓ cleaved caspase-3 | [198] |
6. The Relationship between lncRNAs and Immunotherapy
7. The Prospective Clinical Application of lncRNAs for Overcoming MDR in BC Patients
7.1. Association of lncRNAs and Patients with BC
7.2. The Potential Roles of lncRNAs in Clinical Applications
8. Conclusions and Perspectives
Author Contributions
Funding
Conflicts of Interest
References
- Loibl, S.; Poortmans, P.; Morrow, M.; Denkert, C.; Curigliano, G. Breast cancer. Lancet 2021, 397, 1750–1769. [Google Scholar] [CrossRef]
- Nikolaou, M.; Pavlopoulou, A.; Georgakilas, A.G.; Kyrodimos, E. The challenge of drug resistance in cancer treatment: A current overview. Clin. Exp. Metastasis 2018, 35, 309–318. [Google Scholar] [CrossRef] [PubMed]
- Qian, X.; Zhao, J.; Yeung, P.Y.; Zhang, Q.C.; Kwok, C.K. Revealing lncRNA Structures and Interactions by Sequencing-Based Approaches. Trends. Biochem. Sci. 2019, 44, 33–52. [Google Scholar] [CrossRef] [PubMed]
- Shi, Q.; Li, Y.; Li, S.; Jin, L.; Lai, H.; Wu, Y.; Cai, Z.; Zhu, M.; Li, Q.; Li, Y.; et al. LncRNA DILA1 inhibits Cyclin D1 degradation and contributes to tamoxifen resistance in breast cancer. Nat. Commun. 2020, 11, 5513. [Google Scholar] [CrossRef]
- Dong, H.; Hu, J.; Zou, K.; Ye, M.; Chen, Y.; Wu, C.; Chen, X.; Han, M. Activation of LncRNA TINCR by H3K27 acetylation promotes Trastuzumab resistance and epithelial-mesenchymal transition by targeting MicroRNA-125b in breast Cancer. Mol. Cancer 2019, 18, 3. [Google Scholar] [CrossRef]
- Jin, X.; Ge, L.-P.; Li, D.-Q.; Shao, Z.-M.; Di, G.-H.; Xu, X.-E.; Jiang, Y.-Z. LncRNA TROJAN promotes proliferation and resistance to CDK4/6 inhibitor via CDK2 transcriptional activation in ER+ breast cancer. Mol. Cancer 2020, 19, 87. [Google Scholar] [CrossRef]
- Wu, Q.; Yang, Z.; Nie, Y.; Shi, Y.; Fan, D. Multi-drug resistance in cancer chemotherapeutics: Mechanisms and lab approaches. Cancer Lett. 2014, 347, 159–166. [Google Scholar] [CrossRef]
- Giaccone, G.; Pinedo, H.M. Drug Resistance. Oncologist 1996, 1, 82–87. [Google Scholar] [CrossRef] [Green Version]
- Li, W.; Zhang, H.; Assaraf, Y.G.; Zhao, K.; Xu, X.; Xie, J.; Yang, D.-H.; Chen, Z.-S. Overcoming ABC transporter-mediated multidrug resistance: Molecular mechanisms and novel therapeutic drug strategies. Drug Resist. Updates Rev. Comment. Antimicrob. Anticancer Chemother. 2016, 27, 14–29. [Google Scholar] [CrossRef]
- Kapse-Mistry, S.; Govender, T.; Srivastava, R.; Yergeri, M. Nanodrug delivery in reversing multidrug resistance in cancer cells. Front. Pharmacol. 2014, 5, 159. [Google Scholar]
- Perez, J.; Bardin, C.; Rigal, C.; Anthony, B.; Rousseau, R.; Dutour, A. Anti-MDR1 siRNA restores chemosensitivity in chemoresistant breast carcinoma and osteosarcoma cell lines. Anticancer Res. 2011, 31, 2813–2820. [Google Scholar] [PubMed]
- Mechetner, E.B.; Roninson, I.B. Efficient inhibition of P-glycoprotein-mediated multidrug resistance with a monoclonal antibody. Proc. Natl. Acad. Sci. USA 1992, 89, 5824–5828. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kartal-Yandim, M.; Adan-Gokbulut, A.; Baran, Y. Molecular mechanisms of drug resistance and its reversal in cancer. Crit. Rev. Biotechnol. 2016, 36, 716–726. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Koski, A.; Raki, M.; Nokisalmi, P.; Liikanen, I.; Kangasniemi, L.; Joensuu, T.; Kanerva, A.; Pesonen, S.; Alemany, R.; Hemminki, A. Verapamil results in increased blood levels of oncolytic adenovirus in treatment of patients with advanced cancer. Mol. Ther. J. Am. Soc. Gene Ther. 2012, 20, 221–229. [Google Scholar] [CrossRef]
- Assaraf, Y.G.; Brozovic, A.; Gonçalves, A.C.; Jurkovicova, D.; Linē, A.; Machuqueiro, M.; Saponara, S.; Sarmento-Ribeiro, A.B.; Xavier, C.P.R.; Vasconcelos, M.H. The multi-factorial nature of clinical multidrug resistance in cancer. Drug Resist. Updates Rev. Comment. Antimicrob. Anticancer Chemother. 2019, 46, 100645. [Google Scholar] [CrossRef]
- Leonard, G.D.; Fojo, T.; Bates, S.E. The role of ABC transporters in clinical practice. Oncologist 2003, 8, 411–424. [Google Scholar] [CrossRef]
- Lin, W.; Zhou, Q.; Wang, C.-Q.; Zhu, L.; Bi, C.; Zhang, S.; Wang, X.; Jin, H. LncRNAs regulate metabolism in cancer. Int. J. Biol. Sci. 2020, 16, 1194–1206. [Google Scholar] [CrossRef]
- Bridges, M.C.; Daulagala, A.C.; Kourtidis, A. LNCcation: lncRNA localization and function. J. Cell Biol. 2021, 220, e202009045. [Google Scholar] [CrossRef]
- Peng, W.X.; Koirala, P.; Mo, Y.Y. LncRNA-mediated regulation of cell signaling in cancer. Oncogene 2017, 36, 5661–5667. [Google Scholar] [CrossRef]
- Tam, C.; Wong, J.H.; Tsui, S.K.W.; Zuo, T.; Chan, T.F.; Ng, T.B. LncRNAs with miRNAs in regulation of gastric, liver, and colorectal cancers: Updates in recent years. Appl. Microbiol. Biotechnol. 2019, 103, 4649–4677. [Google Scholar] [CrossRef]
- Sartori, D.A.; Chan, D.W. Biomarkers in prostate cancer: What’s new? Curr. Opin. Oncol. 2014, 26, 259–264. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Xue, W.-J.; Ying, X.-L.; Jiang, J.-H.; Xu, Y.-H. Prostate cancer antigen 3 as a biomarker in the urine for prostate cancer diagnosis: A meta-analysis. J. Cancer Res. Ther 2014, 10, C218–C221. [Google Scholar] [CrossRef] [PubMed]
- Hu, B.; Yang, H.; Yang, H. Diagnostic value of urine prostate cancer antigen 3 test using a cutoff value of 35 μg/L in patients with prostate cancer. Tumour Biol. J. Int. Soc. Oncodev. Biol. Med. 2014, 35, 8573–8580. [Google Scholar] [CrossRef] [PubMed]
- Rinn, J.L.; Chang, H.Y. Genome regulation by long noncoding RNAs. Annu. Rev. Biochem. 2012, 81, 145–166. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Arita, T.; Ichikawa, D.; Konishi, H.; Komatsu, S.; Shiozaki, A.; Shoda, K.; Kawaguchi, T.; Hirajima, S.; Nagata, H.; Kubota, T.; et al. Circulating long non-coding RNAs in plasma of patients with gastric cancer. Anticancer Res. 2013, 33, 3185–3193. [Google Scholar]
- Yuan, S.; Xiang, Y.; Guo, X.; Zhang, Y.; Li, C.; Xie, W.; Wu, N.; Wu, L.; Cai, T.; Ma, X.; et al. Circulating Long Noncoding RNAs Act as Diagnostic Biomarkers in Non-Small Cell Lung Cancer. Front. Oncol 2020, 10, 537120. [Google Scholar] [CrossRef]
- Tang, H.; Wu, Z.; Zhang, J.; Su, B. Salivary lncRNA as a potential marker for oral squamous cell carcinoma diagnosis. Mol. Med. Rep. 2013, 7, 761–766. [Google Scholar] [CrossRef] [Green Version]
- Bolha, L.; Ravnik-Glavač, M.; Glavač, D. Long Noncoding RNAs as Biomarkers in Cancer. Dis. Markers 2017, 2017, 7243968. [Google Scholar] [CrossRef] [Green Version]
- Zhang, K.; Shi, H.; Xi, H.; Wu, X.; Cui, J.; Gao, Y.; Liang, W.; Hu, C.; Liu, Y.; Li, J.; et al. Genome-Wide lncRNA Microarray Profiling Identifies Novel Circulating lncRNAs for Detection of Gastric Cancer. Theranostics 2017, 7, 213–227. [Google Scholar] [CrossRef]
- Lu, L.; Li, J.; Moussaoui, M.; Boix, E. Immune Modulation by Human Secreted RNases at the Extracellular Space. Front. Immunol. 2018, 9, 1012. [Google Scholar] [CrossRef] [Green Version]
- Clark, M.B.; Johnston, R.L.; Inostroza-Ponta, M.; Fox, A.H.; Fortini, E.; Moscato, P.; Dinger, M.E.; Mattick, J.S. Genome-wide analysis of long noncoding RNA stability. Genome Res. 2012, 22, 885–898. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Giraldez, M.D.; Spengler, R.M.; Etheridge, A.; Goicochea, A.J.; Tuck, M.; Choi, S.W.; Galas, D.J.; Tewari, M. Phospho-RNA-seq: A modified small RNA-seq method that reveals circulating mRNA and lncRNA fragments as potential biomarkers in human plasma. EMBO J. 2019, 38, e101695. [Google Scholar] [CrossRef] [PubMed]
- Charles Richard, J.L.; Eichhorn, P.J.A. Platforms for Investigating LncRNA Functions. SLAS Technol. 2018, 23, 493–506. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Galamb, O.; Barták, B.K.; Kalmár, A.; Nagy, Z.B.; Szigeti, K.A.; Tulassay, Z.; Igaz, P.; Molnár, B. Diagnostic and prognostic potential of tissue and circulating long non-coding RNAs in colorectal tumors. World J. Gastroenterol. 2019, 25, 5026–5048. [Google Scholar] [CrossRef] [PubMed]
- Long, Y.; Wang, X.; Youmans, D.T.; Cech, T.R. How do lncRNAs regulate transcription? Sci. Adv. 2017, 3, eaao2110. [Google Scholar] [CrossRef] [Green Version]
- Taft, R.J.; Pang, K.C.; Mercer, T.R.; Dinger, M.; Mattick, J.S. Non-coding RNAs: Regulators of disease. J. Pathol. 2010, 220, 126–139. [Google Scholar] [CrossRef]
- D’Arcy, M.S. Cell death: A review of the major forms of apoptosis, necrosis and autophagy. Cell Biol. Int. 2019, 43, 582–592. [Google Scholar] [CrossRef]
- Grilo, A.L.; Mantalaris, A. Apoptosis: A mammalian cell bioprocessing perspective. Biotechnol. Adv. 2019, 37, 459–475. [Google Scholar] [CrossRef]
- Pistritto, G.; Trisciuoglio, D.; Ceci, C.; Garufi, A.; D’Orazi, G. Apoptosis as anticancer mechanism: Function and dysfunction of its modulators and targeted therapeutic strategies. Aging 2016, 8, 603–619. [Google Scholar] [CrossRef] [Green Version]
- Xu, J.-H.; Hu, S.-L.; Shen, G.-D.; Shen, G. Tumor suppressor genes and their underlying interactions in paclitaxel resistance in cancer therapy. Cancer Cell Int. 2016, 16, 13. [Google Scholar] [CrossRef] [Green Version]
- Yuan, Z.; Jiang, H.; Zhu, X.; Liu, X.; Li, J. Ginsenoside Rg3 promotes cytotoxicity of Paclitaxel through inhibiting NF-κB signaling and regulating Bax/Bcl-2 expression on triple-negative breast cancer. Biomed. Pharmacother. 2017, 89, 227–232. [Google Scholar] [CrossRef] [PubMed]
- Ma, Y.; Zhou, G.; Li, M.; Hu, D.; Zhang, L.; Liu, P.; Lin, K. Long noncoding RNA DANCR mediates cisplatin resistance in glioma cells via activating AXL/PI3K/Akt/NF-κB signaling pathway. Neurochem. Int. 2018, 118, 233–241. [Google Scholar] [CrossRef] [PubMed]
- Sun, Z.-Y.; Jian, Y.-K.; Zhu, H.-Y.; Li, B. lncRNAPVT1 targets miR-152 to enhance chemoresistance of osteosarcoma to gemcitabine through activating c-MET/PI3K/AKT pathway. Pathol. Res. Pract. 2019, 215, 555–563. [Google Scholar] [CrossRef] [PubMed]
- Wang, H.; Fang, L.; Jiang, J.; Kuang, Y.; Wang, B.; Shang, X.; Han, P.; Li, Y.; Liu, M.; Zhang, Z.; et al. The cisplatin-induced lncRNA PANDAR dictates the chemoresistance of ovarian cancer via regulating SFRS2-mediated p53 phosphorylation. Cell Death Dis. 2018, 9, 1103. [Google Scholar] [CrossRef] [PubMed]
- Sun, Y.; Hu, B.; Wang, Q.; Ye, M.; Qiu, Q.; Zhou, Y.; Zeng, F.; Zhang, X.; Guo, Y.; Guo, L. Long non-coding RNA HOTTIP promotes BCL-2 expression and induces chemoresistance in small cell lung cancer by sponging miR-216a. Cell Death Dis. 2018, 9, 85. [Google Scholar] [CrossRef] [Green Version]
- Collette, J.; Le Bourhis, X.; Adriaenssens, E. Regulation of Human Breast Cancer by the Long Non-Coding RNA H19. Int. J. Mol. Sci. 2017, 18, 2319. [Google Scholar] [CrossRef] [Green Version]
- Li, Y.; Ma, H.-Y.; Hu, X.-W.; Qu, Y.-Y.; Wen, X.; Zhang, Y.; Xu, Q.-Y. LncRNA H19 promotes triple-negative breast cancer cells invasion and metastasis through the p53/TNFAIP8 pathway. Cancer Cell Int. 2020, 20, 200. [Google Scholar] [CrossRef]
- Han, J.; Han, B.; Wu, X.; Hao, J.; Dong, X.; Shen, Q.; Pang, H. Knockdown of lncRNA H19 restores chemo-sensitivity in paclitaxel-resistant triple-negative breast cancer through triggering apoptosis and regulating Akt signaling pathway. Toxicol. Appl. Pharmacol. 2018, 359, 55–61. [Google Scholar] [CrossRef]
- Si, X.; Zang, R.; Zhang, E.; Liu, Y.; Shi, X.; Zhang, E.; Shao, L.; Li, A.; Yang, N.; Han, X.; et al. LncRNA H19 confers chemoresistance in ERα-positive breast cancer through epigenetic silencing of the pro-apoptotic gene BIK. Oncotarget 2016, 7, 81452–81462. [Google Scholar] [CrossRef] [Green Version]
- Zheng, S.; Li, M.; Miao, K.; Xu, H. lncRNA GAS5-promoted apoptosis in triple-negative breast cancer by targeting miR-378a-5p/SUFU signaling. J. Cell. Biochem. 2020, 121, 2225–2235. [Google Scholar] [CrossRef]
- Esmatabadi, M.J.D.; Motamedrad, M.; Sadeghizadeh, M. Down-regulation of lncRNA, GAS5 decreases chemotherapeutic effect of dendrosomal curcumin (DNC) in breast cancer cells. Phytomedicine 2018, 42, 56–65. [Google Scholar] [CrossRef] [PubMed]
- Deocesano-Pereira, C.; Machado, R.A.C.; De Jesus-Ferreira, H.C.; Marchini, T.; Pereira, T.F.; Carreira, A.C.O.; Sogayar, M.C. Functional impact of the long non-coding RNA deletion by CRISPR/Cas9 in the human triple negative metastatic Hs578T cancer cell line. Oncol. Lett. 2019, 18, 5941–5951. [Google Scholar] [CrossRef] [PubMed]
- Zhu, M.; Wang, F.; Mi, H.; Li, L.; Wang, J.; Han, M.; Gu, Y. Long noncoding RNA MEG3 suppresses cell proliferation, migration and invasion, induces apoptosis and paclitaxel-resistance via miR-4513/PBLD axis in breast cancer cells. Cell Cycle 2020, 19, 3277–3288. [Google Scholar] [CrossRef]
- Gao, X.; Qin, T.; Mao, J.; Zhang, J.; Fan, S.; Lu, Y.; Sun, Z.; Zhang, Q.; Song, B.; Li, L. PTENP1/miR-20a/PTEN axis contributes to breast cancer progression by regulating PTEN via PI3K/AKT pathway. J. Exp. Clin. Cancer Res. 2019, 38, 256. [Google Scholar] [CrossRef] [PubMed]
- Wu, C.; Luo, J. Long Non-Coding RNA (lncRNA) Urothelial Carcinoma-Associated 1 (UCA1) Enhances Tamoxifen Resistance in Breast Cancer Cells via Inhibiting mTOR Signaling Pathway. Med. Sci. Monit. 2016, 22, 3860–3867. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Li, Z.; Yu, D.; Li, H.; Lv, Y.; Li, S. Long non-coding RNA UCA1 confers tamoxifen resistance in breast cancer endocrinotherapy through regulation of the EZH2/p21 axis and the PI3K/AKT signaling pathway. Int. J. Oncol. 2019, 54, 1033–1042. [Google Scholar] [CrossRef]
- Dong, H.; Wang, W.; Chen, R.; Zhang, Y.; Zou, K.; Ye, M.; He, X.; Zhang, F.; Han, J. Exosome-mediated transfer of lncRNA-SNHG14 promotes trastuzumab chemoresistance in breast cancer. Int. J. Oncol. 2018, 53, 1013–1026. [Google Scholar] [CrossRef] [Green Version]
- Qu, R.; Hu, C.; Tang, Y.; Yu, Q.; Shi, G. Long Non-coding RNA BLACAT1 Induces Tamoxifen Resistance in Human Breast Cancer by Regulating miR-503/Bcl-2 Axis. Cancer Manag. Res. 2020, 12, 1771–1777. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Liang, Y.; Song, X.; Li, Y.; Sang, Y.; Zhang, N.; Zhang, H.; Liu, Y.; Duan, Y.; Chen, B.; Guo, R.; et al. A novel long non-coding RNA-PRLB acts as a tumor promoter through regulating miR-4766-5p/SIRT1 axis in breast cancer. Cell. Death Dis. 2018, 9, 563. [Google Scholar] [CrossRef] [Green Version]
- Liang, Y.; Li, Y.; Song, X.; Zhang, N.; Sang, Y.; Zhang, H.; Liu, Y.; Chen, B.; Zhao, W.; Wang, L.; et al. Long noncoding RNA LINP1 acts as an oncogene and promotes chemoresistance in breast cancer. Cancer Biol. Ther. 2018, 19, 120–131. [Google Scholar] [CrossRef] [Green Version]
- Zheng, R.; Jia, J.; Guan, L.; Yuan, H.; Liu, K.; Liu, C.; Ye, W.; Liao, Y.; Lin, S.; Huang, O. Long noncoding RNA lnc-LOC645166 promotes adriamycin resistance via NF-κB/GATA3 axis in breast cancer. Aging 2020, 12, 8893–8912. [Google Scholar] [CrossRef] [PubMed]
- Xu, S.; Wang, P.; Zhang, J.; Wu, H.; Sui, S.; Zhang, J.; Wang, Q.; Qiao, K.; Yang, W.; Xu, H.; et al. Ai-lncRNA EGOT enhancing autophagy sensitizes paclitaxel cytotoxicity via upregulation of ITPR1 expression by RNA-RNA and RNA-protein interactions in human cancer. Mol. Cancer 2019, 18, 89. [Google Scholar] [CrossRef] [PubMed]
- Li, Y.; Jiang, B.; Zhu, H.; Qu, X.; Zhao, L.; Tan, Y.; Jiang, Y.; Liao, M.; Wu, X. Inhibition of long non-coding RNA ROR reverses resistance to Tamoxifen by inducing autophagy in breast cancer. Tumour Biol. 2017, 39, 1010428317705790. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Lu, P.-W.; Li, L.; Wang, F.; Gu, Y.-T. Inhibitory role of large intergenic noncoding RNA-ROR on tamoxifen resistance in the endocrine therapy of breast cancer by regulating the PI3K/Akt/mTOR signaling pathway. J. Cell. Physiol. 2019, 234, 1904–1912. [Google Scholar] [CrossRef]
- Wang, J.; Xie, S.; Yang, J.; Xiong, H.; Jia, Y.; Zhou, Y.; Chen, Y.; Ying, X.; Chen, C.; Ye, C.; et al. The long noncoding RNA H19 promotes tamoxifen resistance in breast cancer via autophagy. J. Hematol. Oncol. 2019, 12, 81. [Google Scholar] [CrossRef]
- Han, M.; Qian, X.; Cao, H.; Wang, F.; Li, X.; Han, N.; Yang, X.; Yang, Y.; Dou, D.; Hu, J.; et al. lncRNA ZNF649-AS1 Induces Trastuzumab Resistance by Promoting ATG5 Expression and Autophagy. Mol. Ther. J. Am. Soc. Gene Ther. 2020, 28, 2488–2502. [Google Scholar] [CrossRef]
- Li, J.; Zhang, J.; Jin, L.; Deng, H.; Wu, J. Silencing Inhibits Breast Cancer Cell Growth the mTOR Pathway. Anticancer Res. 2018, 38, 3427–3434. [Google Scholar] [CrossRef]
- Wu, J.; Chen, H.; Ye, M.; Wang, B.; Zhang, Y.; Sheng, J.; Meng, T.; Chen, H. Downregulation of long noncoding RNA HCP5 contributes to cisplatin resistance in human triple-negative breast cancer via regulation of PTEN expression. Biomed. Pharmacother. 2019, 115, 108869, Corrigendum in Biomed. Pharmacother. 2020, 122, 109789. [Google Scholar] [CrossRef]
- Gu, J.; Wang, Y.; Wang, X.; Zhou, D.; Shao, C.; Zhou, M.; He, Z. Downregulation of lncRNA GAS5 confers tamoxifen resistance by activating miR-222 in breast cancer. Cancer Lett. 2018, 434, 1–10. [Google Scholar] [CrossRef]
- Zhu, H.-Y.; Bai, W.-D.; Ye, X.-M.; Yang, A.-G.; Jia, L.-T. Long non-coding RNA UCA1 desensitizes breast cancer cells to trastuzumab by impeding miR-18a repression of Yes-associated protein 1. Biochem. Biophys. Res. Commun. 2018, 496, 1308–1313. [Google Scholar] [CrossRef]
- Liu, C.; Jiang, F.; Zhang, X.; Xu, X. Long Non-Coding RNA UCA1 Modulates Paclitaxel Resistance in Breast Cancer via miR-613/CDK12 Axis. Cancer Manag. Res. 2020, 12, 2777–2788. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Li, W.; Zhai, L.; Wang, H.; Liu, C.; Zhang, J.; Chen, W.; Wei, Q. Downregulation of LncRNA GAS5 causes trastuzumab resistance in breast cancer. Oncotarget 2016, 7, 27778–27786. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Chen, J.; Zhu, M.; Zou, L.; Xia, J.; Huang, J.; Deng, Q.; Xu, R. Long non-coding RNA LINC-PINT attenuates paclitaxel resistance in triple-negative breast cancer cells via targeting the RNA-binding protein NONO. Acta Biochim. Biophys. Sin. 2020, 52, 801–809. [Google Scholar] [CrossRef] [PubMed]
- Wang, Y.; Zhou, P.; Li, P.; Yang, F.; Gao, X.-Q. Long non-coding RNA H19 regulates proliferation and doxorubicin resistance in MCF-7 cells by targeting PARP1. Bioengineered 2020, 11, 536–546. [Google Scholar] [CrossRef] [PubMed]
- García-Venzor, A.; Mandujano-Tinoco, E.A.; Ruiz-Silvestre, A.; Sánchez, J.M.; Lizarraga, F.; Zampedri, C.; Melendez-Zajgla, J.; Maldonado, V. lncMat2B regulated by severe hypoxia induces cisplatin resistance by increasing DNA damage repair and tumor-initiating population in breast cancer cells. Carcinogenesis 2020, 41, 1485–1497. [Google Scholar] [CrossRef] [PubMed]
- Shi, Y.F.; Lu, H.; Wang, H.B. Downregulated lncRNA ADAMTS9-AS2 in breast cancer enhances tamoxifen resistance by activating microRNA-130a-5p. Eur. Rev. Med. Pharmacol. Sci. 2019, 23, 1563–1573. [Google Scholar] [PubMed]
- Mizushima, N.; Komatsu, M. Autophagy: Renovation of cells and tissues. Cell 2011, 147, 728–741. [Google Scholar] [CrossRef] [Green Version]
- Mizushima, N.; Levine, B.; Cuervo, A.M.; Klionsky, D.J. Autophagy fights disease through cellular self-digestion. Nature 2008, 451, 1069–1075. [Google Scholar] [CrossRef] [Green Version]
- Shintani, T.; Klionsky, D.J. Autophagy in health and disease: A double-edged sword. Science 2004, 306, 990–995. [Google Scholar] [CrossRef] [Green Version]
- Maiuri, M.C.; Zalckvar, E.; Kimchi, A.; Kroemer, G. Self-eating and self-killing: Crosstalk between autophagy and apoptosis. Nat. Rev. Mol. Cell Biol. 2007, 8, 741–752. [Google Scholar] [CrossRef]
- Ravegnini, G.; Sammarini, G.; Nannini, M.; Pantaleo, M.A.; Biasco, G.; Hrelia, P.; Angelini, S. Gastrointestinal stromal tumors (GIST): Facing cell death between autophagy and apoptosis. Autophagy 2017, 13, 452–463. [Google Scholar] [CrossRef] [PubMed]
- John, S.; Nayvelt, I.; Hsu, H.-C.; Yang, P.; Liu, W.; Das, G.M.; Thomas, T.; Thomas, T.J. Regulation of estrogenic effects by beclin 1 in breast cancer cells. Cancer Res. 2008, 68, 7855–7863. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Jackson, S.P.; Bartek, J. The DNA-damage response in human biology and disease. Nature 2009, 461, 1071–1078. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Palchaudhuri, R.; Hergenrother, P.J. DNA as a target for anticancer compounds: Methods to determine the mode of binding and the mechanism of action. Curr. Opin. Biotechnol. 2007, 18, 497–503. [Google Scholar] [CrossRef]
- Nikitaki, Z.; Michalopoulos, I.; Georgakilas, A.G. Molecular inhibitors of DNA repair: Searching for the ultimate tumor killing weapon. Future Med. Chem. 2015, 7, 1543–1558. [Google Scholar] [CrossRef] [PubMed]
- Du, P.; Zhao, H.; Peng, R.; Liu, Q.; Yuan, J.; Peng, G.; Liao, Y. LncRNA-XIST interacts with to modulate the chemoresistance of glioma cell to TMZ through DNA mismatch repair pathway. Biosci. Rep. 2017, 37, BSR20170696. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Wang, X.; Liu, H.; Shi, L.; Yu, X.; Gu, Y.; Sun, X. LINP1 facilitates DNA damage repair through non-homologous end joining (NHEJ) pathway and subsequently decreases the sensitivity of cervical cancer cells to ionizing radiation. Cell Cycle 2018, 17, 439–447. [Google Scholar] [CrossRef]
- Chen, C.-C.; Chen, C.-Y.; Wang, S.-H.; Yeh, C.-T.; Su, S.-C.; Ueng, S.-H.; Chuang, W.-Y.; Hsueh, C.; Wang, T.-H. Melatonin Sensitizes Hepatocellular Carcinoma Cells to Chemotherapy Through Long Non-Coding RNA RAD51-AS1-Mediated Suppression of DNA Repair. Cancers 2018, 10, 320. [Google Scholar] [CrossRef] [Green Version]
- Shen, W.H.; Balajee, A.S.; Wang, J.; Wu, H.; Eng, C.; Pandolfi, P.P.; Yin, Y. Essential role for nuclear PTEN in maintaining chromosomal integrity. Cell 2007, 128, 157–170. [Google Scholar] [CrossRef] [Green Version]
- Bassi, C.; Ho, J.; Srikumar, T.; Dowling, R.J.O.; Gorrini, C.; Miller, S.J.; Mak, T.W.; Neel, B.G.; Raught, B.; Stambolic, V. Nuclear PTEN controls DNA repair and sensitivity to genotoxic stress. Science 2013, 341, 395–399. [Google Scholar] [CrossRef] [Green Version]
- Dillon, L.M.; Miller, T.W. Therapeutic targeting of cancers with loss of PTEN function. Curr. Drug Targets 2014, 15, 65–79. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Li, L.; Ross, A.H. Why is PTEN an important tumor suppressor? J. Cell. Biochem. 2007, 102, 1368–1374. [Google Scholar] [CrossRef] [PubMed]
- He, J.; Kang, X.; Yin, Y.; Chao, K.S.C.; Shen, W.H. PTEN regulates DNA replication progression and stalled fork recovery. Nat. Commun. 2015, 6, 7620. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Feng, J.; Liang, J.; Li, J.; Li, Y.; Liang, H.; Zhao, X.; McNutt, M.A.; Yin, Y. PTEN Controls the DNA Replication Process through MCM2 in Response to Replicative Stress. Cell Rep. 2015, 13, 1295–1303. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Wang, G.; Li, Y.; Wang, P.; Liang, H.; Cui, M.; Zhu, M.; Guo, L.; Su, Q.; Sun, Y.; McNutt, M.A.; et al. PTEN regulates RPA1 and protects DNA replication forks. Cell Res. 2015, 25, 1189–1204. [Google Scholar] [CrossRef] [Green Version]
- van Ree, J.H.; Nam, H.-J.; Jeganathan, K.B.; Kanakkanthara, A.; van Deursen, J.M. Pten regulates spindle pole movement through Dlg1-mediated recruitment of Eg5 to centrosomes. Nat. Cell Biol. 2016, 18, 814–821. [Google Scholar] [CrossRef]
- He, J.; Zhang, Z.; Ouyang, M.; Yang, F.; Hao, H.; Lamb, K.L.; Yang, J.; Yin, Y.; Shen, W.H. PTEN regulates EG5 to control spindle architecture and chromosome congression during mitosis. Nat. Commun. 2016, 7, 12355. [Google Scholar] [CrossRef]
- Zhang, Z.; Hou, S.-Q.; He, J.; Gu, T.; Yin, Y.; Shen, W.H. PTEN regulates PLK1 and controls chromosomal stability during cell division. Cell Cycle 2016, 15, 2476–2485. [Google Scholar] [CrossRef] [Green Version]
- Sonnenblick, A.; de Azambuja, E.; Azim, H.A.; Piccart, M. An update on PARP inhibitors-moving to the adjuvant setting. Nat. Rev. Clin. Oncol. 2015, 12, 27–41. [Google Scholar] [CrossRef]
- Brandmaier, A.; Hou, S.-Q.; Shen, W.H. Cell Cycle Control by PTEN. J. Mol. Biol. 2017, 429, 2265–2277. [Google Scholar] [CrossRef]
- Coffman, J.A. Cell cycle development. Dev. Cell 2004, 6, 321–327. [Google Scholar] [CrossRef] [Green Version]
- Malumbres, M.; Barbacid, M. Cell cycle, CDKs and cancer: A changing paradigm. Nat. Rev. Cancer 2009, 9, 153–166. [Google Scholar] [CrossRef] [PubMed]
- Asghar, U.; Witkiewicz, A.K.; Turner, N.C.; Knudsen, E.S. The history and future of targeting cyclin-dependent kinases in cancer therapy. Nat. Rev. Drug Discov. 2015, 14, 130–146. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Otto, T.; Sicinski, P. Cell cycle proteins as promising targets in cancer therapy. Nat. Rev. Cancer 2017, 17, 93–115. [Google Scholar] [CrossRef] [Green Version]
- Wang, T.H.; Wang, H.S.; Soong, Y.K. Paclitaxel-induced cell death: Where the cell cycle and apoptosis come together. Cancer 2000, 88, 2619–2628. [Google Scholar] [CrossRef]
- Tishler, R.B.; Geard, C.R.; Hall, E.J.; Schiff, P.B. Taxol sensitizes human astrocytoma cells to radiation. Cancer Res. 1992, 52, 3495–3497. [Google Scholar]
- Tishler, R.B.; Schiff, P.B.; Geard, C.R.; Hall, E.J. Taxol: A novel radiation sensitizer. Int. J. Radiat. Oncol. Biol. Phys. 1992, 22, 613–617. [Google Scholar] [CrossRef]
- Rowinsky, E.K.; Donehower, R.C. Paclitaxel (taxol). N. Engl. J. Med. 1995, 332, 1004–1014. [Google Scholar] [CrossRef]
- Zhang, H.; Zhao, B.; Wang, X.; Zhang, F.; Yu, W. LINC00511 knockdown enhances paclitaxel cytotoxicity in breast cancer via regulating miR-29c/CDK6 axis. Life Sci. 2019, 228, 135–144. [Google Scholar] [CrossRef]
- Rader, J.; Russell, M.R.; Hart, L.S.; Nakazawa, M.S.; Belcastro, L.T.; Martinez, D.; Li, Y.; Carpenter, E.L.; Attiyeh, E.F.; Diskin, S.J.; et al. Dual CDK4/CDK6 inhibition induces cell-cycle arrest and senescence in neuroblastoma. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 2013, 19, 6173–6182. [Google Scholar] [CrossRef] [Green Version]
- Wander, S.A.; Mayer, E.L.; Burstein, H.J. Blocking the Cycle: Cyclin-Dependent Kinase 4/6 Inhibitors in Metastatic, Hormone Receptor-Positive Breast Cancer. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2017, 35, 2866–2870. [Google Scholar] [CrossRef] [PubMed]
- Braal, C.L.; Jongbloed, E.M.; Wilting, S.M.; Mathijssen, R.H.J.; Koolen, S.L.W.; Jager, A. Inhibiting CDK4/6 in Breast Cancer with Palbociclib, Ribociclib, and Abemaciclib: Similarities and Differences. Drugs 2021, 81, 317–331. [Google Scholar] [CrossRef] [PubMed]
- Piezzo, M.; Cocco, S.; Caputo, R.; Cianniello, D.; Gioia, G.D.; Lauro, V.D.; Fusco, G.; Martinelli, C.; Nuzzo, F.; Pensabene, M.; et al. Targeting Cell Cycle in Breast Cancer: CDK4/6 Inhibitors. Int. J. Mol. Sci. 2020, 21, 6479. [Google Scholar] [CrossRef] [PubMed]
- Mitobe, Y.; Ikeda, K.; Suzuki, T.; Takagi, K.; Kawabata, H.; Horie-Inoue, K.; Inoue, S. ESR1-Stabilizing Long Noncoding RNA Promotes Hormone-Refractory Breast Cancer Progression. Mol. Cell. Biol. 2019, 39, e00261-19. [Google Scholar] [CrossRef] [PubMed]
- Zheng, P.; Dong, L.; Zhang, B.; Dai, J.; Zhang, Y.; Wang, Y.; Qin, S. Long noncoding RNA CASC2 promotes paclitaxel resistance in breast cancer through regulation of miR-18a-5p/CDK19. Histochem. Cell. Biol. 2019, 152, 281–291. [Google Scholar] [CrossRef]
- Shin, V.Y.; Chen, J.; Cheuk, I.W.-Y.; Siu, M.-T.; Ho, C.-W.; Wang, X.; Jin, H.; Kwong, A. Long non-coding RNA NEAT1 confers oncogenic role in triple-negative breast cancer through modulating chemoresistance and cancer stemness. Cell Death Dis. 2019, 10, 270. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Sun, W.; Xu, X.; Jiang, Y.; Jin, X.; Zhou, P.; Liu, Y.; Guo, Y.; Ma, D.; Zuo, W.; Huang, S.; et al. Transcriptome analysis of luminal breast cancer reveals a role for LOL in tumor progression and tamoxifen resistance. Int. J. Cancer 2019, 145, 842–856. [Google Scholar] [CrossRef]
- Li, X.; Wu, Y.; Liu, A.; Tang, X. Long non-coding RNA UCA1 enhances tamoxifen resistance in breast cancer cells through a miR-18a-HIF1α feedback regulatory loop. Tumour Biol. J. Int. Soc. Oncodev. Biol. Med. 2016, 37, 14733–14743. [Google Scholar] [CrossRef]
- Sun, W.; Li, A.-Q.; Zhou, P.; Jiang, Y.-Z.; Jin, X.; Liu, Y.-R.; Guo, Y.-J.; Yang, W.-T.; Shao, Z.-M.; Xu, X.-E. DSCAM-AS1 regulates the G/S cell cycle transition and is an independent prognostic factor of poor survival in luminal breast cancer patients treated with endocrine therapy. Cancer Med. 2018, 7, 6137–6146. [Google Scholar] [CrossRef] [Green Version]
- Ma, Y.; Bu, D.; Long, J.; Chai, W.; Dong, J. LncRNA DSCAM-AS1 acts as a sponge of miR-137 to enhance Tamoxifen resistance in breast cancer. J. Cell. Physiol. 2019, 234, 2880–2894. [Google Scholar] [CrossRef]
- Wang, R.; Zhang, T.; Yang, Z.; Jiang, C.; Seng, J. Long non-coding RNA FTH1P3 activates paclitaxel resistance in breast cancer through miR-206/ABCB1. J. Cell. Mol. Med. 2018, 22, 4068–4075. [Google Scholar] [CrossRef] [PubMed]
- Feng, J.; Wen, T.; Li, Z.; Feng, L.; Zhou, L.; Yang, Z.; Xu, L.; Shi, S.; Hou, K.; Shen, J.; et al. Cross-talk between the ER pathway and the lncRNA MAFG-AS1/miR-339-5p/CDK2 axis promotes progression of ER+ breast cancer and confers tamoxifen resistance. Aging 2020, 12, 20658–20683. [Google Scholar] [CrossRef] [PubMed]
- Jiang, M.; Huang, O.; Xie, Z.; Wu, S.; Zhang, X.; Shen, A.; Liu, H.; Chen, X.; Wu, J.; Lou, Y.; et al. A novel long non-coding RNA-ARA: Adriamycin resistance-associated. Biochem. Pharmacol. 2014, 87, 254–283. [Google Scholar] [CrossRef] [PubMed]
- Chen, Z.; Pan, T.; Jiang, D.; Jin, L.; Geng, Y.; Feng, X.; Shen, A.; Zhang, L. The lncRNA-GAS5/miR-221-3p/DKK2 Axis Modulates ABCB1-Mediated Adriamycin Resistance of Breast Cancer via the Wnt/β-Catenin Signaling Pathway. Mol. Ther. Nucleic Acids 2020, 19, 1434–1448. [Google Scholar] [CrossRef]
- Zeng, Y.; Wang, G.; Zhou, C.-F.; Zhang, H.-B.; Sun, H.; Zhang, W.; Zhou, H.-H.; Liu, R.; Zhu, Y.-S. LncRNA Profile Study Reveals a Three-LncRNA Signature Associated With the Pathological Complete Response Following Neoadjuvant Chemotherapy in Breast Cancer. Front. Pharmacol. 2019, 10, 574. [Google Scholar] [CrossRef]
- Chang, L.; Hu, Z.; Zhou, Z.; Zhang, H. Linc00518 Contributes to Multidrug Resistance Through Regulating the MiR-199a/MRP1 Axis in Breast Cancer. Cell. Physiol. Biochem. Internat. J. Exp. Cell. Phys. Biochem. Pharmacol. 2018, 48, 16–28. [Google Scholar] [CrossRef]
- Zhu, Q.-N.; Wang, G.; Guo, Y.; Peng, Y.; Zhang, R.; Deng, J.-L.; Li, Z.-X.; Zhu, Y.-S. LncRNA H19 is a major mediator of doxorubicin chemoresistance in breast cancer cells through a cullin4A-MDR1 pathway. Oncotarget 2017, 8, 91990–92003. [Google Scholar] [CrossRef] [Green Version]
- Li, Y.; Wang, Y.; Wang, H.; Zhang, L.; Ding, Y.; Chen, S.; Yang, Q.; Chen, C. Effects of lncRNA RP11-770J1.3 and TMEM25 expression on paclitaxel resistance in human breast cancer cells. Zhejiang Da Xue Xue Bao Yi Xue Ban 2017, 46, 364–370. [Google Scholar]
- Ma, T.; Liang, Y.; Li, Y.; Song, X.; Zhang, N.; Li, X.; Chen, B.; Zhao, W.; Wang, L.; Yang, Q. LncRNA LINP1 confers tamoxifen resistance and negatively regulated by ER signaling in breast cancer. Cell. Signal. 2020, 68, 109536. [Google Scholar] [CrossRef]
- Yao, N.; Fu, Y.; Chen, L.; Liu, Z.; He, J.; Zhu, Y.; Xia, T.; Wang, S. Long non-coding RNA NONHSAT101069 promotes epirubicin resistance, migration, and invasion of breast cancer cells through NONHSAT101069/miR-129-5p/Twist1 axis. Oncogene 2019, 38, 7216–7233. [Google Scholar] [CrossRef]
- Xiu, D.-H.; Liu, G.-F.; Yu, S.-N.; Li, L.-Y.; Zhao, G.-Q.; Liu, L.; Li, X.-F. Long non-coding RNA LINC00968 attenuates drug resistance of breast cancer cells through inhibiting the Wnt2/β-catenin signaling pathway by regulating WNT2. J. Exp. Clin. Cancer Res. 2019, 38, 94. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Gao, H.; Hao, G.; Sun, Y.; Li, L.; Wang, Y. Long noncoding RNA H19 mediated the chemosensitivity of breast cancer cells via Wnt pathway and EMT process. OncoTarg. Ther. 2018, 11, 8001–8012. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Yan, L.; Yang, S.; Yue, C.-X.; Wei, X.-Y.; Peng, W.; Dong, Z.-Y.; Xu, H.-N.; Chen, S.-L.; Wang, W.-R.; Chen, C.-J.; et al. Long noncoding RNA H19 acts as a miR-340-3p sponge to promote epithelial-mesenchymal transition by regulating YWHAZ expression in paclitaxel-resistant breast cancer cells. Environ. Toxicol. 2020, 35, 1015–1028. [Google Scholar] [CrossRef] [PubMed]
- Zhang, X.; Wang, M.; Sun, H.; Zhu, T.; Wang, X. Downregulation of LINC00894-002 Contributes to Tamoxifen Resistance by Enhancing the TGF-β Signaling Pathway. Biochemistry. 2018, 83, 603–611. [Google Scholar] [CrossRef] [PubMed]
- Li, X.; Wang, S.; Li, Z.; Long, X.; Guo, Z.; Zhang, G.; Zu, J.; Chen, Y.; Wen, L. The lncRNA NEAT1 facilitates cell growth and invasion via the miR-211/HMGA2 axis in breast cancer. Int. J. Biol. Macromol. 2017, 105, 346–353. [Google Scholar] [CrossRef] [PubMed]
- Zhang, H.-Y.; Liang, F.; Zhang, J.-W.; Wang, F.; Wang, L.; Kang, X.-G. Effects of long noncoding RNA-ROR on tamoxifen resistance of breast cancer cells by regulating microRNA-205. Cancer Chemother. Pharmacol. 2017, 79, 327–337. [Google Scholar] [CrossRef]
- Du, C.; Wang, Y.; Zhang, Y.; Zhang, J.; Zhang, L.; Li, J. LncRNA DLX6-AS1 Contributes to Epithelial-Mesenchymal Transition and Cisplatin Resistance in Triple-negative Breast Cancer via Modulating Mir-199b-5p/Paxillin Axis. Cell Transplant. 2020, 29, 963689720929983. [Google Scholar] [CrossRef]
- Chen, Y.-M.; Liu, Y.; Wei, H.-Y.; Lv, K.-Z.; Fu, P. Linc-ROR induces epithelial-mesenchymal transition and contributes to drug resistance and invasion of breast cancer cells. Tumour Biol. J. Int. Soc. Oncodev. Biol. Med. 2016, 37, 10861–10870. [Google Scholar] [CrossRef]
- Shi, S.-J.; Wang, L.-J.; Yu, B.; Li, Y.-H.; Jin, Y.; Bai, X.-Z. LncRNA-ATB promotes trastuzumab resistance and invasion-metastasis cascade in breast cancer. Oncotarget 2015, 6, 11652–11663. [Google Scholar] [CrossRef] [Green Version]
- Zhang, H.; Zhang, X.-Y.; Kang, X.-N.; Jin, L.-J.; Wang, Z.-Y. LncRNA-SNHG7 Enhances Chemotherapy Resistance and Cell Viability of Breast Cancer Cells by Regulating miR-186. Cancer Manag. Res. 2020, 12, 10163–10172. [Google Scholar] [CrossRef]
- Li, Z.-H.; Yu, N.-S.; Deng, Q.; Zhang, Y.; Hu, Y.-Y.; Liu, G.; Huang, K. LncRNA SNHG7 Mediates the Chemoresistance and Stemness of Breast Cancer by Sponging miR-34a. Front. Oncol. 2020, 10, 592757. [Google Scholar] [CrossRef] [PubMed]
- Tang, L.; Chen, Y.; Chen, H.; Jiang, P.; Yan, L.; Mo, D.; Tang, X.; Yan, F. Promotes TGF-β-Induced Epithelial-Mesenchymal Transition and Enhances Chemoresistance in Triple-Negative Breast Cancer Cells via ANXA1. Front. Oncol. 2020, 10, 280. [Google Scholar] [CrossRef] [PubMed]
- Han, M.; Gu, Y.; Lu, P.; Li, J.; Cao, H.; Li, X.; Qian, X.; Yu, C.; Yang, Y.; Yang, X.; et al. Exosome-mediated lncRNA AFAP1-AS1 promotes trastuzumab resistance through binding with AUF1 and activating ERBB2 translation. Mol. Cancer 2020, 19, 26. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Cairns, J.; Ingle, J.N.; Kalari, K.R.; Shepherd, L.E.; Kubo, M.; Goetz, M.P.; Weinshilboum, R.M.; Wang, L. The lncRNA MIR2052HG regulates ERα levels and aromatase inhibitor resistance through LMTK3 by recruiting EGR1. Breast Cancer Res. BCR 2019, 21, 47. [Google Scholar] [CrossRef] [Green Version]
- Wang, Z.; Katsaros, D.; Biglia, N.; Shen, Y.; Loo, L.; Yu, X.; Lin, H.; Fu, Y.; Chu, W.-M.; Fei, P.; et al. ERα upregulates the expression of long non-coding RNA LINC00472 which suppresses the phosphorylation of NF-κB in breast cancer. Breast Cancer Res. Treat. 2019, 175, 353–368. [Google Scholar] [CrossRef]
- Basak, P.; Chatterjee, S.; Bhat, V.; Su, A.; Jin, H.; Lee-Wing, V.; Liu, Q.; Hu, P.; Murphy, L.C.; Raouf, A. Long Non-Coding RNA H19 Acts as an Estrogen Receptor Modulator that is Required for Endocrine Therapy Resistance in ER+ Breast Cancer Cells. Cell. Physiol. Biochem. Internat. J. Exp. Cell. Phys. Biochem. Pharmacol. 2018, 51, 1518–1532. [Google Scholar] [CrossRef]
- Gooding, A.J.; Zhang, B.; Gunawardane, L.; Beard, A.; Valadkhan, S.; Schiemann, W.P. The lncRNA BORG facilitates the survival and chemoresistance of triple-negative breast cancers. Oncogene 2019, 38, 2020–2041. [Google Scholar] [CrossRef]
- Dong, H.; Wang, W.; Mo, S.; Chen, R.; Zou, K.; Han, J.; Zhang, F.; Hu, J. SP1-induced lncRNA AGAP2-AS1 expression promotes chemoresistance of breast cancer by epigenetic regulation of MyD88. J. Exp. Clin. Cancer Res CR 2018, 37, 202. [Google Scholar] [CrossRef]
- Dong, H.; Wang, W.; Mo, S.; Liu, Q.; Chen, X.; Chen, R.; Zhang, Y.; Zou, K.; Ye, M.; He, X.; et al. Long non-coding RNA SNHG14 induces trastuzumab resistance of breast cancer via regulating PABPC1 expression through H3K27 acetylation. J. Cell. Mol. Med. 2018, 22, 4935–4947. [Google Scholar] [CrossRef] [Green Version]
- Pan, Y.; Pan, Y.; Cheng, Y.; Yang, F.; Yao, Z.; Wang, O. Knockdown of LncRNA MAPT-AS1 inhibites proliferation and migration and sensitizes cancer cells to paclitaxel by regulating MAPT expression in ER-negative breast cancers. Cell Biosci. 2018, 8, 7. [Google Scholar] [CrossRef] [Green Version]
- Peng, W.-X.; Huang, J.-G.; Yang, L.; Gong, A.-H.; Mo, Y.-Y. Linc-RoR promotes MAPK/ERK signaling and confers estrogen-independent growth of breast cancer. Mol. Cancer 2017, 16, 161. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Xue, X.; Yang, Y.A.; Zhang, A.; Fong, K.W.; Kim, J.; Song, B.; Li, S.; Zhao, J.C.; Yu, J. LncRNA HOTAIR enhances ER signaling and confers tamoxifen resistance in breast cancer. Oncogene 2016, 35, 2746–2755. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Zhuang, Y.; Nguyen, H.T.; Burow, M.E.; Zhuo, Y.; El-Dahr, S.S.; Yao, X.; Cao, S.; Flemington, E.K.; Nephew, K.P.; Fang, F.; et al. Elevated expression of long intergenic non-coding RNA HOTAIR in a basal-like variant of MCF-7 breast cancer cells. Mol. Carcinog. 2015, 54, 1656–1667. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Lin, X.; Dinglin, X.; Cao, S.; Zheng, S.; Wu, C.; Chen, W.; Li, Q.; Hu, Q.; Zheng, F.; Wu, Z.; et al. Enhancer-Driven lncRNA BDNF-AS Induces Endocrine Resistance and Malignant Progression of Breast Cancer through the RNH1/TRIM21/mTOR Cascade. Cell Rep. 2020, 31, 107753. [Google Scholar] [CrossRef] [PubMed]
- Godinho, M.F.E.; Sieuwerts, A.M.; Look, M.P.; Meijer, D.; Foekens, J.A.; Dorssers, L.C.J.; van Agthoven, T. Relevance of BCAR4 in tamoxifen resistance and tumour aggressiveness of human breast cancer. Br. J. Cancer 2010, 103, 1284–1291. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Gottesman, M.M.; Fojo, T.; Bates, S.E. Multidrug resistance in cancer: Role of ATP-dependent transporters. Nat. Rev. Cancer 2002, 2, 48–58. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Dean, M.; Rzhetsky, A.; Allikmets, R. The human ATP-binding cassette (ABC) transporter superfamily. Genome Res. 2001, 11, 1156–1166. [Google Scholar] [CrossRef]
- Dean, M. ABC transporters, drug resistance, and cancer stem cells. J. Mammary Gland Biol. Neoplasia 2009, 14, 3–9. [Google Scholar] [CrossRef]
- Zhu, J.; Zhang, R.; Yang, D.; Li, J.; Yan, X.; Jin, K.; Li, W.; Liu, X.; Zhao, J.; Shang, W.; et al. Knockdown of Long Non-Coding RNA XIST Inhibited Doxorubicin Resistance in Colorectal Cancer by Upregulation of miR-124 and Downregulation of SGK1. Cell. Physiol. Biochem. Internat. J. Exp. Cell. Phys. Biochem. Pharmacol. 2018, 51, 113–128. [Google Scholar] [CrossRef]
- Zhang, Z.; Xiong, R.; Li, C.; Xu, M.; Guo, M. LncRNA TUG1 promotes cisplatin resistance in esophageal squamous cell carcinoma cells by regulating Nrf2. Acta Biochim. Biophys. Sin. 2019, 51, 826–833. [Google Scholar] [CrossRef]
- Song, L.; Zhou, Z.; Gan, Y.; Li, P.; Xu, Y.; Zhang, Z.; Luo, F.; Xu, J.; Zhou, Q.; Dai, F. Long noncoding RNA OIP5-AS1 causes cisplatin resistance in osteosarcoma through inducing the LPAATβ/PI3K/AKT/mTOR signaling pathway by sponging the miR-340-5p. J. Cell. Biochem. 2019, 120, 9656–9666. [Google Scholar] [CrossRef] [PubMed]
- Mou, S.-J.; Yang, P.-F.; Liu, Y.-P.; Xu, N.; Jiang, W.-W.; Yue, W.-J. BCLAF1 promotes cell proliferation, invasion and drug-resistance though targeting lncRNA NEAT1 in hepatocellular carcinoma. Life Sci. 2020, 242, 117177. [Google Scholar] [CrossRef] [PubMed]
- Martin-Orozco, E.; Sanchez-Fernandez, A.; Ortiz-Parra, I.; Ayala-San Nicolas, M. WNT Signaling in Tumors: The Way to Evade Drugs and Immunity. Front. Immunol. 2019, 10, 2854. [Google Scholar] [CrossRef] [PubMed]
- Kalluri, R.; Weinberg, R.A. The basics of epithelial-mesenchymal transition. J. Clin. Investing. 2009, 119, 1420–1428. [Google Scholar] [CrossRef] [Green Version]
- Sommers, C.L.; Heckford, S.E.; Skerker, J.M.; Worland, P.; Torri, J.A.; Thompson, E.W.; Byers, S.W.; Gelmann, E.P. Loss of epithelial markers and acquisition of vimentin expression in adriamycin- and vinblastine-resistant human breast cancer cell lines. Cancer Res. 1992, 52, 5190–5197. [Google Scholar]
- Arumugam, T.; Ramachandran, V.; Fournier, K.F.; Wang, H.; Marquis, L.; Abbruzzese, J.L.; Gallick, G.E.; Logsdon, C.D.; McConkey, D.J.; Choi, W. Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer. Cancer Res. 2009, 69, 5820–5828. [Google Scholar] [CrossRef] [Green Version]
- McConkey, D.J.; Choi, W.; Marquis, L.; Martin, F.; Williams, M.B.; Shah, J.; Svatek, R.; Das, A.; Adam, L.; Kamat, A.; et al. Role of epithelial-to-mesenchymal transition (EMT) in drug sensitivity and metastasis in bladder cancer. Cancer Metastasis Rev. 2009, 28, 335–344. [Google Scholar] [CrossRef] [Green Version]
- Huang, J.; Li, H.; Ren, G. Epithelial-mesenchymal transition and drug resistance in breast cancer (Review). Int. J. Oncol. 2015, 47, 840–848. [Google Scholar] [CrossRef] [Green Version]
- De Craene, B.; Berx, G. Regulatory networks defining EMT during cancer initiation and progression. Nat. Rev. Cancer 2013, 13, 97–110. [Google Scholar] [CrossRef]
- Kim, H.-J.; Litzenburger, B.C.; Cui, X.; Delgado, D.A.; Grabiner, B.C.; Lin, X.; Lewis, M.T.; Gottardis, M.M.; Wong, T.W.; Attar, R.M.; et al. Constitutively active type I insulin-like growth factor receptor causes transformation and xenograft growth of immortalized mammary epithelial cells and is accompanied by an epithelial-to-mesenchymal transition mediated by NF-kappaB and snail. Mol. Cell. Biol. 2007, 27, 3165–3175. [Google Scholar] [CrossRef] [Green Version]
- Timmerman, L.A.; Grego-Bessa, J.; Raya, A.; Bertrán, E.; Pérez-Pomares, J.M.; Díez, J.; Aranda, S.; Palomo, S.; McCormick, F.; Izpisúa-Belmonte, J.C.; et al. Notch promotes epithelial-mesenchymal transition during cardiac development and oncogenic transformation. Genes. Dev. 2004, 18, 99–115. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Yook, J.I.; Li, X.-Y.; Ota, I.; Fearon, E.R.; Weiss, S.J. Wnt-dependent regulation of the E-cadherin repressor snail. J. Biol. Chem. 2005, 280, 11740–11748. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Syn, W.-K.; Jung, Y.; Omenetti, A.; Abdelmalek, M.; Guy, C.D.; Yang, L.; Wang, J.; Witek, R.P.; Fearing, C.M.; Pereira, T.A.; et al. Hedgehog-mediated epithelial-to-mesenchymal transition and fibrogenic repair in nonalcoholic fatty liver disease. Gastroenterology 2009, 137, 1478–1488. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Yuan, Y.; Liao, H.; Pu, Q.; Ke, X.; Hu, X.; Ma, Y.; Luo, X.; Jiang, Q.; Gong, Y.; Wu, M.; et al. miR-410 induces both epithelial-mesenchymal transition and radioresistance through activation of the PI3K/mTOR pathway in non-small cell lung cancer. Signal. Transduct. Target. Ther. 2020, 5, 85. [Google Scholar] [CrossRef] [PubMed]
- Grotegut, S.; von Schweinitz, D.; Christofori, G.; Lehembre, F. Hepatocyte growth factor induces cell scattering through MAPK/Egr-1-mediated upregulation of Snail. EMBO J. 2006, 25, 3534–3545. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Sun, X.; Huang, T.; Liu, Z.; Sun, M.; Luo, S. LncRNA SNHG7 contributes to tumorigenesis and progression in breast cancer by interacting with miR-34a through EMT initiation and the Notch-1 pathway. Eur. J. Pharmacol. 2019, 856, 172407. [Google Scholar] [CrossRef] [PubMed]
- Nassar, D.; Blanpain, C. Cancer Stem Cells: Basic Concepts and Therapeutic Implications. Annu. Rev. Pathol. 2016, 11, 47–76. [Google Scholar] [CrossRef]
- Shibue, T.; Weinberg, R.A. EMT, CSCs, and drug resistance: The mechanistic link and clinical implications. Nat. Rev. Clin. Oncol. 2017, 14, 611–629. [Google Scholar] [CrossRef] [Green Version]
- Mani, S.A.; Guo, W.; Liao, M.-J.; Eaton, E.N.; Ayyanan, A.; Zhou, A.Y.; Brooks, M.; Reinhard, F.; Zhang, C.C.; Shipitsin, M.; et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008, 133, 704–715. [Google Scholar] [CrossRef] [Green Version]
- Levina, V.; Marrangoni, A.M.; DeMarco, R.; Gorelik, E.; Lokshin, A.E. Drug-selected human lung cancer stem cells: Cytokine network, tumorigenic and metastatic properties. PLoS ONE 2008, 3, e3077. [Google Scholar] [CrossRef] [Green Version]
- Dallas, N.A.; Xia, L.; Fan, F.; Gray, M.J.; Gaur, P.; van Buren, G.; Samuel, S.; Kim, M.P.; Lim, S.J.; Ellis, L.M. Chemoresistant colorectal cancer cells, the cancer stem cell phenotype, and increased sensitivity to insulin-like growth factor-I receptor inhibition. Cancer Res. 2009, 69, 1951–1957. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Huang, H.; Sabari, B.R.; Garcia, B.A.; Allis, C.D.; Zhao, Y. SnapShot: Histone modifications. Cell 2014, 159, 458. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Dawson, M.A.; Kouzarides, T. Cancer epigenetics: From mechanism to therapy. Cell 2012, 150, 12–27. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Matei, D.; Fang, F.; Shen, C.; Schilder, J.; Arnold, A.; Zeng, Y.; Berry, W.A.; Huang, T.; Nephew, K.P. Epigenetic resensitization to platinum in ovarian cancer. Cancer Res. 2012, 72, 2197–2205. [Google Scholar] [CrossRef] [Green Version]
- Balch, C.; Nephew, K.P. Epigenetic targeting therapies to overcome chemotherapy resistance. Adv. Exp. Med. Biol. 2013, 754, 285–311. [Google Scholar]
- Wilting, R.H.; Dannenberg, J.-H. Epigenetic mechanisms in tumorigenesis, tumor cell heterogeneity and drug resistance. Drug Resist. Updates Rev. Commen. Antimicrobe. Anticancer Chemother. 2012, 15, 21–38. [Google Scholar] [CrossRef] [Green Version]
- Kouzarides, T. Chromatin modifications and their function. Cell 2007, 128, 693–705. [Google Scholar] [CrossRef] [Green Version]
- Whiteside, T.L. The tumor microenvironment and its role in promoting tumor growth. Oncogene 2008, 27, 5904–5912. [Google Scholar] [CrossRef] [Green Version]
- Boelens, M.C.; Wu, T.J.; Nabet, B.Y.; Xu, B.; Qiu, Y.; Yoon, T.; Azzam, D.J.; Twyman-Saint Victor, C.; Wiemann, B.Z.; Ishwaran, H.; et al. Exosome transfer from stromal to breast cancer cells regulates therapy resistance pathways. Cell 2014, 159, 499–513. [Google Scholar] [CrossRef] [Green Version]
- Kalluri, R.; LeBleu, V.S. The biology function and biomedical applications of exosomes. Science 2020, 367, eaau6977. [Google Scholar] [CrossRef]
- Pefanis, E.; Wang, J.; Rothschild, G.; Lim, J.; Kazadi, D.; Sun, J.; Federation, A.; Chao, J.; Elliott, O.; Liu, Z.-P.; et al. RNA exosome-regulated long non-coding RNA transcription controls super-enhancer activity. Cell 2015, 161, 774–789. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Qu, L.; Ding, J.; Chen, C.; Wu, Z.-J.; Liu, B.; Gao, Y.; Chen, W.; Liu, F.; Sun, W.; Li, X.-F.; et al. Exosome-Transmitted lncARSR Promotes Sunitinib Resistance in Renal Cancer by Acting as a Competing Endogenous RNA. Cancer Cell 2016, 29, 653–668. [Google Scholar] [CrossRef] [PubMed]
- Zhang, W.; Cai, X.; Yu, J.; Lu, X.; Qian, Q.; Qian, W. Exosome-mediated transfer of lncRNA RP11-838N2.4 promotes erlotinib resistance in non-small cell lung cancer. Int. J. Oncol. 2018, 53, 527–538. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kang, M.; Ren, M.; Li, Y.; Fu, Y.; Deng, M.; Li, C. Exosome-mediated transfer of lncRNA PART1 induces gefitinib resistance in esophageal squamous cell carcinoma via functioning as a competing endogenous RNA. J. Exp. Clin. Cancer Res. CR 2018, 37, 171. [Google Scholar] [CrossRef] [PubMed]
- Wang, J.; Lv, B.; Su, Y.; Wang, X.; Bu, J.; Yao, L. Exosome-Mediated Transfer of lncRNA HOTTIP Promotes Cisplatin Resistance in Gastric Cancer Cells by Regulating HMGA1/miR-218 Axis. OncoTarg. Ther. 2019, 12, 11325–11338. [Google Scholar] [CrossRef] [Green Version]
- Li, Z.; Niu, H.; Qin, Q.; Yang, S.; Wang, Q.; Yu, C.; Wei, Z.; Jin, Z.; Wang, X.; Yang, A.; et al. lncRNA UCA1 Mediates Resistance to Cisplatin by Regulating the miR-143/FOSL2-Signaling Pathway in Ovarian Cancer. Mol. Ther. Nucleic Acids 2019, 17, 92–101. [Google Scholar] [CrossRef] [Green Version]
- Luo, X.; Wei, J.; Yang, F.-L.; Pang, X.-X.; Shi, F.; Wei, Y.-X.; Liao, B.-Y.; Wang, J.-L. Exosomal lncRNA HNF1A-AS1 affects cisplatin resistance in cervical cancer cells through regulating microRNA-34b/TUFT1 axis. Cancer Cell Int. 2019, 19, 323. [Google Scholar] [CrossRef] [Green Version]
- Xu, C.G.; Yang, M.F.; Ren, Y.Q.; Wu, C.H.; Wang, L.Q. Exosomes mediated transfer of lncRNA UCA1 results in increased tamoxifen resistance in breast cancer cells. Eur. Rev. Med. Pharmacol. Sci. 2016, 20, 4362–4368. [Google Scholar]
- Ni, C.; Fang, Q.-Q.; Chen, W.-Z.; Jiang, J.-X.; Jiang, Z.; Ye, J.; Zhang, T.; Yang, L.; Meng, F.-B.; Xia, W.-J.; et al. Breast cancer-derived exosomes transmit lncRNA SNHG16 to induce CD73+γδ1 Treg cells. Signal. Transduct. Target. Ther. 2020, 5, 41. [Google Scholar] [CrossRef]
- Wang, X.; Pei, X.; Guo, G.; Qian, X.; Dou, D.; Zhang, Z.; Xu, X.; Duan, X. Exosome-mediated transfer of long noncoding RNA H19 induces doxorubicin resistance in breast cancer. J. Cell. Physiol. 2020, 235, 6896–6904. [Google Scholar] [CrossRef]
- Chen, F.; Chen, J.; Yang, L.; Liu, J.; Zhang, X.; Zhang, Y.; Tu, Q.; Yin, D.; Lin, D.; Wong, P.-P.; et al. Extracellular vesicle-packaged HIF-1α-stabilizing lncRNA from tumour-associated macrophages regulates aerobic glycolysis of breast cancer cells. Nat. Cell. Biol. 2019, 21, 498–510. [Google Scholar] [CrossRef] [PubMed]
- Zheng, Z.; Chen, M.; Xing, P.; Yan, X.; Xie, B. Increased Expression of Exosomal AGAP2-AS1 (AGAP2 Antisense RNA 1) In Breast Cancer Cells Inhibits Trastuzumab-Induced Cell Cytotoxicity. Med. Sci. Monit. 2019, 25, 2211–2220. [Google Scholar] [CrossRef] [PubMed]
- Kalluri, R. The biology and function of exosomes in cancer. J. Clinic. Investing. 2016, 126, 1208–1215. [Google Scholar] [CrossRef] [PubMed]
- Zhang, Y.; Li, X.; Kong, X.; Zhang, M.; Wang, D.; Liu, Y.; Lv, K. Long non-coding RNA AK085865 ablation confers susceptibility to viral myocarditis by regulating macrophage polarization. J. Cell. Mol. Med. 2020, 24, 5542–5554. [Google Scholar] [CrossRef] [Green Version]
- Ahmad, I.; Valverde, A.; Ahmad, F.; Naqvi, A.R. Long Noncoding RNA in Myeloid and Lymphoid Cell Differentiation, Polarization and Function. Cells 2020, 9, 269. [Google Scholar] [CrossRef] [Green Version]
- Huang, D.; Chen, J.; Yang, L.; Ouyang, Q.; Li, J.; Lao, L.; Zhao, J.; Liu, J.; Lu, Y.; Xing, Y.; et al. NKILA lncRNA promotes tumor immune evasion by sensitizing T cells to activation-induced cell death. Nat. Immunol. 2018, 19, 1112–1125. [Google Scholar] [CrossRef]
- Hu, Q.; Ye, Y.; Chan, L.-C.; Li, Y.; Liang, K.; Lin, A.; Egranov, S.D.; Zhang, Y.; Xia, W.; Gong, J.; et al. Oncogenic lncRNA downregulates cancer cell antigen presentation and intrinsic tumor suppression. Nat. Immunol. 2019, 20, 835–851. [Google Scholar] [CrossRef]
- Zhang, M.; Wang, N.; Song, P.; Fu, Y.; Ren, Y.; Li, Z.; Wang, J. LncRNA GATA3-AS1 facilitates tumour progression and immune escape in triple-negative breast cancer through destabilization of GATA3 but stabilization of PD-L1. Cell Prolif. 2020, 53, e12855. [Google Scholar] [CrossRef]
- Lai, J.; Chen, B.; Zhang, G.; Li, X.; Mok, H.; Liao, N. Molecular characterization of breast cancer: A potential novel immune-related lncRNAs signature. J. Transl. Med. 2020, 18, 416. [Google Scholar] [CrossRef]
- Ma, W.; Zhao, F.; Yu, X.; Guan, S.; Suo, H.; Tao, Z.; Qiu, Y.; Wu, Y.; Cao, Y.; Jin, F. Immune-related lncRNAs as predictors of survival in breast cancer: A prognostic signature. J. Transl. Med. 2020, 18, 442. [Google Scholar] [CrossRef]
- Jafari, S.H.; Saadatpour, Z.; Salmaninejad, A.; Momeni, F.; Mokhtari, M.; Nahand, J.S.; Rahmati, M.; Mirzaei, H.; Kianmehr, M. Breast cancer diagnosis: Imaging techniques and biochemical markers. J. Cell. Physiol. 2018, 233, 5200–5213. [Google Scholar] [CrossRef] [PubMed]
- Shi, T.; Gao, G.; Cao, Y. Long Noncoding RNAs as Novel Biomarkers Have a Promising Future in Cancer Diagnostics. Dis. Markers 2016, 2016, 9085195. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Qi, P.; Zhou, X.-Y.; Du, X. Circulating long non-coding RNAs in cancer: Current status and future perspectives. Mol. Cancer 2016, 15, 39. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Bertos, N.R.; Park, M. Breast cancer-one term, many entities? J. Clinic. Inv. 2011, 121, 3789–3796. [Google Scholar] [CrossRef] [PubMed]
- Wu, B.; Yuan, Y.; Han, X.; Wang, Q.; Shang, H.; Liang, X.; Jing, H.; Cheng, W. Structure of LINC00511-siRNA-conjugated nanobubbles and improvement of cisplatin sensitivity on triple negative breast cancer. FASEB J. Off. Publ. Fed. Am. Soc. Exp. Biol. 2020, 34, 9713–9726. [Google Scholar] [CrossRef]
- Arun, G.; Diermeier, S.; Akerman, M.; Chang, K.-C.; Wilkinson, J.E.; Hearn, S.; Kim, Y.; MacLeod, A.R.; Krainer, A.R.; Norton, L.; et al. Differentiation of mammary tumors and reduction in metastasis upon Malat1 lncRNA loss. Genes Dev. 2016, 30, 34–51. [Google Scholar] [CrossRef] [Green Version]
- Hao, Q.; Wang, P.; Dutta, P.; Chung, S.; Li, Q.; Wang, K.; Li, J.; Cao, W.; Deng, W.; Geng, Q.; et al. Comp34 displays potent preclinical antitumor efficacy in triple-negative breast cancer via inhibition of NUDT3-AS4, a novel oncogenic long noncoding RNA. Cell Death Dis. 2020, 11, 1052. [Google Scholar] [CrossRef]
Function | LncRNA | Type | Genomic Location | Expression Level * | Resistant Drugs | Cell Lines | Possible Mechanism § | Reference |
---|---|---|---|---|---|---|---|---|
Suppressing apoptosis | GAS5 | Tumor suppressor | chr1q25.1 | ↓ | paclitaxel; cisplatin; dendrosomal curcumin | MDA-MB-231; BT549; MCF-7; SKBR-3 | ↑ miR-378a-5p/↓ SUFU signaling | [50,51] |
MEG3 | Tumor suppressor | chr14q32 | ↓ | doxorubicin; paclitaxel | Hs578T; MCF-7; MDA-MB-231 | ↑ TGF-β and N-cadherin protein; ↓ MMP 2, ZEB 1 and COL3A1 expression; ↓ miR-4513/↑ PBLD axis | [52,53] | |
PTENP1 | Tumor suppressor | N/A° | ↓ | adriamycin | MDA-MB-231; T-47D; MCF-7 | ↑ miR-20a/↓ PTEN axis; ↑ PI3K/AKT pathway | [54] | |
UCA1 | Oncogene | chr19q13.12 | ↑ | tamoxifen | MCF-7; T-47D; LCC2; LCC9 | ↑ EZH2/↓ p21 axis; ↑ PI3K/AKT pathway; ↑ mTOR pathway | [55,56] | |
H19 | Oncogene | chr11p15.5 | ↑ | paclitaxel | MDA-MB-453; MDA-MB-157; MDA-MB-231; ZR-75-1; MCF-7 | ↑ AKT pathway; ↓ BIK; ↓ NOXA | [48,49] | |
SNHG14 | Oncogene | chr15q11.3 | ↑ | trastuzumab | SKBR-3; BT474 | ↑ Bcl-2/↓ BAX signaling pathway | [57] | |
BLACAT1 | Oncogene | chr1q32.1 | ↑ | tamoxifen | T-47D; MCF-7 | ↓ miR-503/↑ Bcl-2 | [58] | |
PRLB | Oncogene | chr8p11.21 | ↑ | 5-fluorouracil | MDA-MB-231 | ↓ miR-4766-5p/↑ SIRT1 axis | [59] | |
LINP1 | Oncogene | chr10 | ↑ | doxorubicin; 5-fluorouracil | MDA-MB-231; MDA-MB-468; MCF-7 | ↓ p53; ↓ E-cadherin; ↑ N-cadherin; ↑ vimentin; ↓ caspase9/Bax | [60] | |
LOC645166 | Oncogene | N/A | ↑ | adriamycin | MDA-MB-231; MCF-7 | ↑ NF-κB/GATA3 axis | [61] | |
Autophagy | EGOT | Tumor suppressor | N/A | ↓ | paclitaxel | MCF-7; T-47D; UACC-812; SK-BR-3; HCC70; MDA-MB-453; MDA-MB-231; MDA-MB-468; BT549; Hs578T | ↑ITPR1 | [62] |
ROR | Oncogene | chr18q21.31 | ↑ | tamoxifen | MDA-MB-231; T-47D; BT474; BCAP-37; ZK-75-1; MCF-7 | ↑ PI3K/Akt/mTOR pathway; ↑ MDR1 and GST-π mRNA; ↓ LC3 and Beclin 1 | [63,64] | |
H19 | Oncogene | chr11p15.5 | ↑ | tamoxifen | MCF-7 | H19/SAHH/DNMT3B axis; ↑ Beclin1 | [65] | |
ZNF649-AS1 | Oncogene | chr19q13.41 | ↑ | trastuzumab | SK-BR-3; BT474 | ↑ ATG5 through associating with PTBP1 | [66] | |
ASAH2B-2 | Oncogene | N/A | ↑ | everolimus | BT474; MCF-7 | ↑ mTOR pathway | [67] | |
DNA-repair | HCP5 | Oncogene | N/A | ↑ | cisplatin | MDA-MB-231 | ↓ PTEN | [68] |
PTENP1 | Tumor suppressor | N/A | ↓ | adriamycin | MDA-MB-231; T-47D; MCF-7 | ↑ miR-20a/↓ PTEN axis; ↑ PI3K/AKT pathway | [54] | |
GAS5 | Tumor suppressor | chr1q25.1 | ↓ | tamoxifen | MCF-7 | ↑ miR-222; ↑ AKT/mTOR pathway; ↓ PTEN | [69] | |
UCA1 | Oncogene | chr19q13.12 | ↑ | trastuzumab | SKBR-3 | ↓ miR-18a/↑Yes-associated protein 1 (YAP1); ↓ PTEN; ↑ CD6 | [70] | |
UCA1 | Oncogene | chr19q13.12 | ↑ | paclitaxel | MCF-7 | ↓ miR-613/↑ CDK12 axis | [71] | |
GAS5 | Tumor suppressor | chr1q25.1 | ↓ | trastuzumab; lapatinib | SKBR-3 | ↑ miR-21; ↓ PTEN; ↑ mTOR; ↑ Ki-67 | [72] | |
LINC-PINT | Tumor suppressor | N/A | ↓ | paclitaxel | MDA-MB-231; BT-20 | ↑ NONO | [73] | |
H19 | Oncogene | chr11p15.5 | ↑ | doxorubicin | MCF-7 | ↓ PARP1 | [74] | |
lncMat2B | Oncogene | N/A | ↑ | cisplatin | MDA-MB-231; MCF-7 | N/A | [75] | |
ADAMTS9-AS2 | Tumor suppressor | N/A | ↓ | tamoxifen | MCF-7 | ↑ microRNA-130a-5p; ↓ PTEN | [76] |
Function | LncRNA | Type | Genomic Location | Expression Level * | Resistant Drugs | Cell Lines | Possible Mechanism § | Reference |
---|---|---|---|---|---|---|---|---|
regulating cell cycle | TMPO-AS1 | Oncogene | N/A° | ↑ | tamoxifen | MCF-7 | stabilize ESR1 mRNA | [114] |
CASC2 | Oncogene | N/A | ↑ | paclitaxel | MDA-MB-231; MCF-7 | ↓ miR-18a-5p/↑ CDK19 axis | [115] | |
LINC00511 | Oncogene | chr17q24.3 | ↑ | paclitaxel | MDA-MB-231; MCF-7; T-47D; Hs-578T | ↓ miR-29c/↑ CDK6 axis | [109] | |
NEAT1 | Oncogene | N/A | ↑ | cisplatin/taxol | MDA-MB-231 | N/A | [116] | |
LOL | Oncogene | N/A | ↑ | tamoxifen | MCF-7 | ↓ let-7 miRNA; ↓ ERα signaling | [117] | |
UCA1 | Oncogene | chr19q13.12 | ↑ | tamoxifen | MCF-7; T-47D; LCC2; LCC9; BT474 | ↑ EZH2/↓ p21 axis; ↑ PI3K/AKT pathway; ↓ miR-18a-↑ HIF1α | [56,118] | |
DSCAM-AS1 | Oncogene | chr21q22.3 | ↑ | tamoxifen | MCF-7; T-47D; SK-BR-3; MDA-MB-231 | ↑ epidermal growth factor receptor pathway substrate 8 (EPS8); ↑ ESR1; ↑ ERα; ↓ miR-137 | [119,120] | |
FTH1P3 | Oncogene | N/A | ↑ | paclitaxel | MCF-7; MDA-MB-231; MDA-MB-468; MDA-MB-453 | ↓ miR-206/↑ ABCB1 | [121] | |
MAFG-AS1 | Oncogene | N/A | ↑ | tamoxifen | MCF-7; BT474; T-47D; MCF10A | ↓ miR-339-5p/↑ CDK2 axis | [122] | |
PRLB | Oncogene | chr8p11.21 | ↑ | 5-fluorouracil | MDA-MB-231 | ↓ miR-4766-5p/↑ SIRT1 axis | [59] | |
GAS5 | Tumor suppressor | chr1q25.1 | ↓ | dendrosomal curcumin (DNC) | MCF7; SKBR-3; MDA-MB-231 | N/A | [51] | |
UCA1 | Oncogene | chr19q13.12 | ↑ | trastuzumab | SKBR-3 | ↓ miR-18a/↑ Yes-associated protein 1 (YAP1); ↓ PTEN; ↑ CD6 | [70] | |
LINP1 | Oncogene | chr10 | ↑ | Doxorubicin; 5-fluorouracil | MDA-MB-231; MDA-MB-468; MCF-7 | ↓ p53; ↓ E-cadherin; ↑ N-cadherin; ↑ vimentin; ↓ caspase9/Bax | [60] | |
TROJAN | Oncogene | N/A | ↑ | palbociclib | MCF7; T47D | ↑ NKRF/CDK2 axis | [6] | |
DILA1 | Oncogene | N/A | ↑ | tamoxifen | MCF-7; 293-T; T47D | ↑ Cyclin D1 | [4] | |
ARA | Oncogene | Xq23 | ↑ | adriamycin | MCF-7 | multiple signaling pathways | [123] | |
drug efflux metabolism | GAS5 | Tumor suppressor | chr1q25.1 | ↓ | adriamycin | MCF-7 | ↑ miR-221-3p/↑ dickkopf 2 (DKK2) axis; ↑ Wnt/b-catenin pathway | [124] |
BC032585 | Tumor suppressor | chr9 | ↓ | taxane; anthracyclines | MDA-MB-231 | ↑ MDR1 | [125] | |
Linc00518 | Oncogene | chr6 | ↑ | multidrug adriamycin; vincristine; paclitaxel | MCF-7 | ↓ miR-199a/↑ MRP1 axis | [126] | |
FTH1P3 | Oncogene | N/A | ↑ | paclitaxel | MCF-7; MDA-MB-231; MDA-MB-468; MDA-MB-453 | ↓ miR-206/↑ ABCB1 | [121] | |
GAS5 | Tumor suppressor | chr1q25.1 | ↓ | tamoxifen | MCF-7 | ↑ miR-222; ↑ AKT/mTOR pathway; ↓ PTEN | [69] | |
ROR | Oncogene | chr18q21.31 | ↑ | tamoxifen | BT474 | ↑ MDR1 and GST-π mRNA; ↓ LC3 and Beclin 1 | [63] | |
H19 | Oncogene | chr11p15.5 | ↑ | doxorubicin; anthracyclines | MCF-7 | ↑ CUL4A-ABCB1/MDR1 pathway | [127] | |
RP11-770J1.3 TMEM25 | Oncogene | N/A | ↑ | paclitaxel | MCF-7 | ↑ MRP, BCRP and MDR1/P-gp | [128] | |
EMT | LINP1 | Oncogene | chr10 | ↑ | tamoxifen | MCF-7; T-47D | ↓ ER expression signaling pathway | [129] |
MEG3 | Tumor suppressor | chr14q32 | ↓ | doxorubicin | Hs578T | ↑ TGF-β and N-cadherin protein; ↓ MMP 2, ZEB 1 and COL3A1 expression | [52] | |
NONHSAT101069 | Oncogene | chr5 | ↑ | epirubicin | MCF-7 | ↓ miR-129-5p/↑ Twist1 axis | [130] | |
NEAT1 | Oncogene | N/A | ↑ | cisplatin/taxol | MDA-MB-231 | N/A | [116] | |
LINC00968 | Tumor suppressor | N/A | ↓ | doxorubicin | MCF-7; KPL-4 | ↑ WNT2; ↑ Wnt2/β-catenin pathway | [131] | |
TINCR | Oncogene | N/A | ↑ | trastuzumab | SKBR-3; BT474 | ↓ miR-125b; ↑ HER-2 and Snail-1 | [5] | |
H19 | Oncogene | chr11p15.5 | ↑ | tamoxifen; paclitaxel | SK-BR-3; MCF-7 | ↑ Wnt pathway; ↓ miR-340-3p/YWHAZ axis | [132,133] | |
PRLB | Oncogene | chr8p11.21 | ↑ | 5-fluorouracil | MDA-MB-231 | ↓ miR-4766-5p/↑ SIRT1 | [59] | |
LINC00894002 | Tumor suppressor | X chromosome | ↓ | tamoxifen | MCF-7 | ↓ miR200/↑ TGFβ2 signaling pathway; ↑ ZEB1 | [134] | |
LINP1 | Oncogene | chr10 | ↑ | doxorubicin; 5-fluorouracil | MDA-MB-231; MDA-MB-468; MCF-7 | ↓ p53; ↓ E-cadherin; ↑ N-cadherin; ↑ vimentin; ↓ caspase9/Bax | [60] | |
NEAT1 | Oncogene | N/A | ↑ | 5-fluorouracil | MCF-7; T-47D; MDA-MB-231; ZR-75-1 | ↓ miR-211/↑ HMGA2 axis | [135] | |
ROR | Oncogene | chr18q21.31 | ↑ | tamoxifen | MDA-MB-231; MCF-7 | ↓ microRNA-205; ↓ E-cadherin; ↑ vimentin; ↑ ZEB1 and ZEB2 | [136] | |
DLX6-AS1 | Oncogene | N/A | ↑ | cisplatin | HCC1599; MDA-MB-231; HCC1806; Hs578T | ↓ miR-199b-5p/paxillin signaling | [137] | |
ROR | Oncogene | chr18q21.31 | ↑ | 5-fluorouracil; paclitaxel | T-47D; MCF-7; SK-BR-3; Bcap-37; MDA-MB-231; MCF10A | ↓ E-cadherin; ↑ vimentin and N-cadherin | [138] | |
ATB | Oncogene | chr14q11.2 | ↑ | trastuzumab | SKBR-3 | ↓ miR-200c; ↑ TGF-β signaling; ↑ ZEB1 and ZNF-217 | [139] | |
SNHG7 | Oncogene | chr9q34.3 | ↑ | trastuzumab; adriamycin; paclitaxel | SKBR3; AU565; MDA-MB-231; MCF10A; MCF-7 | ↓ miR-186; ↓ miR-34a | [140,141] | |
DCST1-AS1 | Oncogene | N/A | ↑ | doxorubicin; paclitaxel | MDA-MB-231; BT-549; T-47D; MCF-7 | ↑ TGF-β/Smad signaling through ANXA1 | [142] | |
epigenetic alteration | AFAP1-AS1 | Oncogene | chr4p16.1 | ↑ | trastuzumab | SKBR-3; BT474 | ↑ translation of ERBB2 mRNA | [143] |
TMPO-AS1 | Oncogene | N/A | ↑ | tamoxifen | MCF-7 | stabilize ESR1 mRNA | [114] | |
ZNF649-AS1 | Oncogene | chr19q13.41 | ↑ | trastuzumab | SK-BR-3; BT474 | ↑ ATG5 through associating with PTBP1 | [66] | |
MIR2052HG | Oncogene | N/A | ↑ | aromatase inhibitor | MDA-MB-231; CAMA-1; Au565; 293-T; MCF-7 | ↑ LMTK3; ↓ AKT/FOXO3-mediated ESR1 transcription; ↓ PKC/MEK/ERK/RSK1 pathway; ↓ ERα degradation | [144] | |
LINC00472 | Tumor suppressor | N/A | ↓ | tamoxifen | MCF-7; T-47D; MDA-MB-231; Hs578T | ↑ phosphorylation NF-κB | [145] | |
UCA1 | Oncogene | chr19q13.12 | ↑ | tamoxifen | MCF-7; T-47D; LCC2; LCC9 | ↑ EZH2/↓ p21 axis; ↑ PI3K/AKT pathway | [56] | |
TINCR | Oncogene | N/A | ↑ | trastuzumab | SKBR-3; BT474 | ↓ miR-125b; ↑ HER-2 and Snail-1 | [5] | |
H19 | Oncogene | chr11p15.5 | ↑ | tamoxifen; fulverstrant | LCC2; LCC9; MCF-7 | ↑ ERα; ↑ Notch, HGF and c-MET signaling | [146] | |
BORG | Oncogene | N/A | ↑ | doxorubicin | D2.OR; 67NR; 4T07; 4T1 | ↑ NF-κB signaling; ↑ RPA1 | [147] | |
AGAP2-AS1 | Oncogene | chr12q14.1 | ↑ | trastuzumab | SKBR-3; BT474 | ↑ MyD88; ↑ NF-κB pathway | [148] | |
SNHG14 | Oncogene | chr15q11.2 | ↑ | trastuzumab | SKBR-3; BT474 | ↑ PABPC1; ↑ Nrf2 pathway | [149] | |
MAPT-AS1 | Oncogene | chr17q21.31 | ↑ | paclitaxel | MDA-MB-231; MDA-MB-468 | ↑ MAPT mRNA | [150] | |
Linc-RoR | Oncogene | N/A | ↑ | tamoxifen | MCF-7 | ↑ MAPK/ERK signaling; ↑ ER signaling; ↓ DUSP7 | [151] | |
HOTAIR | Oncogene | chr12q13.13 | ↑ | tamoxifen; TNF-a | MCF-7; T-47D | ↑ ER signaling; ↑ SRC and p38MAPK kinases; ↑ EZH2 | [152,153] | |
H19 | Oncogene | chr11p15.5 | ↑ | paclitaxel | ZR-75-1; MCF-7 | ↓ BIK; ↓ NOXA | [49] | |
BDNF-AS | Oncogene | chr11p14.1 | ↑ | tamoxifen | MCF-7; T-47D; MDA-MB-231 | ↑ RNH1/TRIM21/mTOR | [154] | |
BCAR4 | Oncogene | chr16p13.13 | ↑ | tamoxifen | ZR-75-1 | ↑ ERBB2/ERBB3 pathway; ↑ AKT | [155] |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Ye, P.; Feng, L.; Shi, S.; Dong, C. The Mechanisms of lncRNA-Mediated Multidrug Resistance and the Clinical Application Prospects of lncRNAs in Breast Cancer. Cancers 2022, 14, 2101. https://0-doi-org.brum.beds.ac.uk/10.3390/cancers14092101
Ye P, Feng L, Shi S, Dong C. The Mechanisms of lncRNA-Mediated Multidrug Resistance and the Clinical Application Prospects of lncRNAs in Breast Cancer. Cancers. 2022; 14(9):2101. https://0-doi-org.brum.beds.ac.uk/10.3390/cancers14092101
Chicago/Turabian StyleYe, Pingting, Lei Feng, Shuo Shi, and Chunyan Dong. 2022. "The Mechanisms of lncRNA-Mediated Multidrug Resistance and the Clinical Application Prospects of lncRNAs in Breast Cancer" Cancers 14, no. 9: 2101. https://0-doi-org.brum.beds.ac.uk/10.3390/cancers14092101